Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

Kangstem Biotech develops technology to isolate the non-hematological system stem cell with conversion and purity from the cord blood and to culture large quantity. Its Furestem therapies include Furestem-AD, Furestem-RA and Furestem-CD. Its businesses include cord blood-derived stem cell therapy business; cord blood-derived stem cell conditioned media business; and stem cell culture media business.

Guangdong Qianhui Biotechnology Co., Ltd., established on 2011-03-22, Business scope includes general business items:Biomedical Technology Development,Technical Services,technical consulting,technology transfer.,The licensing program is:none

Nanjing Drum Tower Hospital is a private company headquartered in China. The firm provides medical services.

Guangdong General Hospital (Chinese: 广东省人民医院 meaning "Guangdong Provincial People's Hospital") is a large hospital, founded in 1946, located in Yuexiu District, Guangzhou, Guangdong, China.

Beijing Dikang Pharmaceutical Investment Management Co., Ltd., established on 2010-12-23, Business scope includes investment management;technology development,transfer,consult;Enterprise Management Services;Medical research and experimental development;Sales of medical devices Class I,Class II,hygiene products,cosmetic,daily necessities;Agent import and export,Import and export;Production of Class I medical devices;Sales of Class III Medical Devices;Production of the second class,Class III medical devices.(Enterprises independently choose operating projects according to law,Carry out business activities;Production of the second class,Class III medical devices,Sales of Class III medical devices and items subject to approval according to law,Carry out business activities in accordance with the approved content after approval by relevant departments;Do not engage in the business activities of projects prohibited and restricted by the city's industrial policies.)

Liwo Biotechnology (Shenzhen) Co., Ltd., established on 2016-12-02, Business scope includes general business items:Technology development in the field of biomedicine,technology transfer,technical consulting,Technical Services;R&D and sales of biological reagents and laboratory consumables;sales of cosmetics.,The licensing program is:

Guangzhou Yueqing Regenerative Medicine Technology Co., Ltd., established on 2015-02-06, Business scope includes engineering and technology research and experimental development;Natural science research and experimental development;Medical Research and Experimental Development;New material technology research and development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Human stem cell technology development and application;New material technology promotion service;Technology intermediary service;Production of special labor protection products;Sales of special labor protection products;Sales of Class II Medical Devices;glasses manufacturing;glasses sales(Contact lenses not included);Cosmetics Wholesale;Cosmetics Retail;Domestic trade agent;New material technology research and development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;Import and export;Technology Import and Export;Cosmetic production;pharmaceutical production

Nanjing Gulou Hospital is a Chinese private company located in Nanjing. The firm operates as a hospital.

Daegu Gyeongbuk Institute of Science and Technology (DGIST) (In Korean 대구경북과학기술원) is a public science and engineering university located in Daegu Metropolitan City, Republic of Korea. Under a Special Act on Support of Scientists and Engineers for Strengthening National Science and Technology Competitiveness, the Korean government enacted Daegu Gyeongbuk Institute of Science and Technology Act (Act No. 6996) and founded DGIST in 2004 as a research institute. In 2008, the act was amended to extend the role of the institute to both research and education, which eventually enabled a transition from a research institute to a university.

Accurate International is engaged in the research and development of regenerative medicines based on the four centers of organoid tissue and disease models. clinical medicine transformation, big data sharing, and smart device development.

Decell Matrix is a high-tech enterprise that focuses on the perfect repair and regeneration of the skeletal muscle system. Based on decellularization technology, Diesel skillfully removes the cellular components of natural tissues and preserves the extracellular matrix (ECM), which is highly homologous between species and has strong regeneration and repair functions. Diesel has been funded by a series of key R&D programs including the Ministry of Science and Technology of the People's Republic of China, and its products can enter the green approval channel to seize market opportunities. Domestic sales cover a wide range. Through Kehui Medical's existing more than 1,000 cooperative hospitals and more than 500 distributors, rapid product coverage is achieved.

Wuhan Junrui Regenerative Medicine Technology Research Co., Ltd., established on 2016-04-07, Business scope includes technology development of stem cell translational medicine platform,technology research;Research on Stem Cell Industrialization Technology;Establishment of a pre-medical model of aging with cardiopulmonary function impairment and research on its medical application.(Projects subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Hangzhou Fengzhehuang Biotechnology Co., Ltd., established on 2018-12-29, Business scope includes general items:R&D and application of cell technology;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;internet sales(Except for products that require a license for sale);Cosmetics Wholesale;Health Consulting Services(Does not include medical services)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).

Regend Therapeutics focuses on the human organ regenerative medicine business and is a global leader in this field. Its core product REGEND001 cell preparation has been accepted by the State Food and Drug Administration and is the world's first autologous stem cell product for respiratory diseases. The company is also the first company in China to be registered by the National Health and Health Commission and the Food and Drug Administration, and is allowed to conduct clinical research on stem cells (Registration No.: CMR-20161214-1002). It is also the first batch of key research and development programs of the Ministry of Science and Technology. And companies that transform research topics. At present, the company has passed ISO9001:2008 quality management system certification, and the stem cell preparation has passed the China Metrology Accreditation (CMA), China Conformity Assessment Committee (CNAS) and IAF International Mutual Recognition. All clinical programs of Jimmy Suisheng are strictly in accordance with the regulations of the National Health Care Commission and the Food and Drug Administration, and are registered with the National Trial Global Database of the National Institutes of Health.

Peking University Third Hospital is a private company headquartered in Beijing, China, that operates as a clinic.